Brief: AB Science Gets Positive Recommendation For masitinib In COVID-19 Study
14/09/2022 17:25
Sept 14 (Reuters) - AB SCIENCE SA ABS.PA :
* POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING
BOARD
TO CONTINUE THE PHASE 2 STUDY EVALUATING THE ANTIVIRAL ACTIVITY
OF MASITINIB IN COVID-19
* STUDY IS TARGETING SAME POPULATION AS REGISTERED ANTIVIRAL
TREATMENTS, NAMELY PAXLOVID (PFIZER) AND MOLNUPIRAVIR (MERCK)
Source text for Eikon: ID:nGNXbBGrRj
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease